Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

2022 ◽  
Author(s):  
Jonathan D Schoenfeld ◽  
Anita Giobbie-Hurder ◽  
Srinika Ranasinghe ◽  
Katrina Z Kao ◽  
Ana Lako ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Low Dose ◽  
Small Cell ◽  
Hypofractionated Radiotherapy ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (6) ◽  
pp. 786-795 ◽  
Author(s):  
Catherine A Shu ◽  
Justin F Gainor ◽  
Mark M Awad ◽  
Codruta Chiuzan ◽  
Claud M Grigg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

scholarly journals Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 984-993 ◽  
Author(s):  
David Planchard ◽  
Benjamin Besse ◽  
Harry J M Groen ◽  
Pierre-Jean Souquet ◽  
Elisabeth Quoix ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
Previously Treated

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (11) ◽  
pp. 1413-1422 ◽  
Author(s):  
Mariano Provencio ◽  
Ernest Nadal ◽  
Amelia Insa ◽  
María Rosario García-Campelo ◽  
Joaquín Casal-Rubio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 ◽  
Vol 18 (10) ◽  
pp. 1307-1316 ◽  
Author(s):  
David Planchard ◽  
Egbert F Smit ◽  
Harry J M Groen ◽  
Julien Mazieres ◽  
Benjamin Besse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

2016 ◽  
Vol 17 (5) ◽  
pp. 642-650 ◽  
Author(s):  
David Planchard ◽  
Tae Min Kim ◽  
Julien Mazieres ◽  
Elisabeth Quoix ◽  
Gregory Riely ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document